Approval · Notice of Compliance 19165 · 2017
YERVOY: Notice of Compliance 19165
Issued April 13, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19165
- Date
- April 13, 2017
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: yervoy in combination with opdivo (nivolumab) for the ttreatment of unresectable or metastatic melanoma in previously untreated adults
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| YERVOY | Not yet assigned | — |
Medicinal ingredients
- IPILIMUMAB 5 MG per ML